SAG
DFTX

SageView Advisory Group’s Definium Therapeutics DFTX Stock Holding History

SageView Advisory Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$81 – 1722
2025
Q4 		$81 Buy
+6
New +$74 ﹤0.01% 2552
2024
Q2 		– Sell
-2,648
Closed -$238K – 654
2024
Q1 		$238K Buy
+2,648
New +$15.1K 0.01% 475

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SageView Advisory Group's DFTX Position: Q1 2026 in Review

SageView Advisory Group sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 6 shares — an estimated $81 sold.

SageView Advisory Group first reported a position in DFTX in Q1 2024 and held it in 2 quarters. The position peaked at $238K in Q1 2024. 248 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • SageView Advisory Group reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 6 Definium Therapeutics shares in Q1 2026, an estimated $81.
  • SageView Advisory Group first reported a position in Definium Therapeutics in Q1 2024 and held it in 2 quarters.
  • SageView Advisory Group's Definium Therapeutics position peaked at $238K in Q1 2024.
  • 248 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.